Defining colon cancer biomarkers by using deep learning

Affiliations

¹ Prolatent Health Technologies, Calgary AB T3G 2P6, Canada. Electronic address: adrian.specogna@prolatent.com.
² Mayo Clinic & Mayo Comprehensive Cancer Center, Rochester, MN 55905, USA.

Comment

Adrian V Specogna et al. Lancet. 2020.

. 2020 Feb 1;395(10221):314-316.

doi: 10.1016/S0140-6736(20)30034-9.

¹ Prolatent Health Technologies, Calgary AB T3G 2P6, Canada. Electronic address: adrian.specogna@prolatent.com.
² Mayo Clinic & Mayo Comprehensive Cancer Center, Rochester, MN 55905, USA.

No abstract available

Comment on

Deep learning for prediction of colorectal cancer outcome: a discovery and validation study.
Skrede OJ, De Raedt S, Kleppe A, Hveem TS, Liestøl K, Maddison J, Askautrud HA, Pradhan M, Nesheim JA, Albregtsen F, Farstad IN, Domingo E, Church DN, Nesbakken A, Shepherd NA, Tomlinson I, Kerr R, Novelli M, Kerr DJ, Danielsen HE. Skrede OJ, et al. Lancet. 2020 Feb 1;395(10221):350-360. doi: 10.1016/S0140-6736(19)32998-8. Lancet. 2020. PMID: 32007170 Clinical Trial.